Health Condition 1: C259- Malignant neoplasm of pancreas, unspecified
Conditions
Interventions
Intervention1: Gemcitabine Injection Concentrate-1gm/10 ml: For Ovarian Cancer:
Dose- 1000mg/m2,
Frequency- Day 1 and 8 of each 21 day cycle,
Mode of Administration- IV,
Duration of treatment- Up to 6
Sponsors
Intas Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Able to give written informed consent for participation in the trial. 2. Male and female patients between the ages of 18 and 65 years. 3. Patients with Histo-pathologically or through Fine Needle Aspiration Cytology (FNAC) confirmed ï?§ Locally Advanced (non-resectable Stage II or Stage III) or Metastatic (Stage IV) Adenocarcinoma of the Pancreas (Gemcitabine as first line treatment) â??ORâ?? ï?§ Pancreatic cancer patients previously treated with 5-FU â??ORâ?? ï?§ Advanced Ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy (Gemcitabine in combination with Carboplatin) 4. Recovered from any toxic effects of previous chemotherapy as judged by the Investigator. 5. Patients if already on Radiotherapy, a gap of at least one week shall be maintained between the last day of radiotherapy and the day of screening 6. Patients with life expectancy of at least 2 months 7. Able to comply with study requirement in opinion of Principal Investigator. 8. Adequate hepatic, renal and hematopoietic function. 9. ECOG Performance Status- 0, 1 or 2 10. In case of female patient the serum pregnancy test at screening visit must be negative.
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity reaction to Gemcitabine and any ingredient of the formulation. 2. Use of any recreational drugs or history of drug addiction. 3. History of psychiatric disorders. 4. A positive hepatitis screen including hepatitis B surface antigen, HCV and HAV antibodies. 5. Known case of HIV infection. 6. Pregnant or breast-feeding women. 7. The receipt of an investigational drug or product, or participation in a drug research study within a period of 60 days prior to the first dose of investigational Product (Elimination half-life of the study drug should be taken into consideration for inclusion of the patient in the study). 8. Any other condition that, in the investigatorâ??s judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study. 9. Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To characterize the pharmacokinetic profile of the sponsorâ??s test formulation relative to that of reference formulation in patients and to assess the bioequivalenceTimepoint: Blood samples will be collected at following time points: Pre-infusion (within 60 minutes prior to infusion), 5, 15 and 30 min during the infusion and 5 min, 10 min, 20 min, 0.5 hrs, 0.75 hrs, 1 hr, 1.5 hrs, 2 hrs, 4 hrs, 6 hrs, 8 hrs and 10 hrs post-infusion (total 16 samples) | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor the safety of the patients, who are exposed to the Investigational Medicinal ProductTimepoint: Screening, Day 0 (check in for period I), Day 07 (check in for period II), End of study. | — |
Countries
India
Contacts
Public ContactDr Manjunath K
Lambda Therapeutic Research Ltd
Outcome results
None listed